Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMirallas Viñas, Oriol
dc.contributor.authorBosch Schips, Marc
dc.contributor.authorPardo Aranda, Nuria
dc.contributor.authorAubanell, Anton
dc.contributor.authorSalcedo Allende, Maria Teresa
dc.contributor.authorCallejo Perez, Ana
dc.contributor.authorIranzo Gómez, Patricia
dc.contributor.authorTabernero Caturla, Josep
dc.contributor.authorFelip Font, Enriqueta
dc.date.accessioned2022-09-05T11:41:30Z
dc.date.available2022-09-05T11:41:30Z
dc.date.issued2022-03
dc.identifier.citationMirallas O, Bosch-Schips M, Pardo N, Aubanell A, Salcedo-Allende MT, Callejo A, et al. Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report. Front Oncol. 2022 Mar;12:837630.
dc.identifier.issn2234-943X
dc.identifier.urihttp://hdl.handle.net/11351/8026
dc.descriptionMetastatic hepatic rupture; Non-small cell lung carcinoma; Tyrosine kinase inhibitor
dc.description.abstractHepatic rupture is a rare complication of solid tumor malignancies, notably in lung adenocarcinomas, and carries an extremely poor overall prognosis. Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma predict benefit with tyrosine kinase inhibitors (TKIs). This case report describes a female patient who presented with a metastatic hepatic rupture and was subsequently diagnosed with EGFR-mutated lung adenocarcinoma. The tumor had an impressive response to TKI inhibitor treatment, reversing her extremely poor, short-term prognosis. We believe this unique case sheds light on the treatment management of hepatic ruptures and supports the high response rate seen with TKIs in EGFR-mutated lung cancers, regardless of the patient’s performance status.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Oncology;12
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectAdenocarcinoma - Tractament
dc.subjectPulmons - Càncer - Tractament
dc.subjectProteïnes quinases - Inhibidors
dc.subject.meshAdenocarcinoma of Lung
dc.subject.mesh/therapy
dc.subject.meshProtein Kinase Inhibitors
dc.titleHepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fonc.2022.837630
dc.subject.decsadenocarcinoma de pulmón
dc.subject.decs/terapia
dc.subject.decsinhibidores de proteínas cinasas
dc.relation.publishversionhttps://doi.org/10.3389/fonc.2022.837630
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Mirallas O, Pardo N, Callejo A, Iranzo P, Tabernero J, Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Bosch-Schips M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Aubanell A] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Salcedo-Allende MT] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid35433405
dc.identifier.wos000788209600001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record